Product Description
RafaelÕs lead compound, CPI-613¨Ê(devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. (Sourced from: https://rafaelpharma.com/research-and-development/cpi-613-drug)
Mechanisms of Action: Pyruvate Dehydrogenase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid LeukemiaFast Track - Pancreatic CancerOrphan Drug - Biliary Tract CancerOrphan Drug - Lymphoma|Burkitt LymphomaOrphan Drug - Sarcoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rafael Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Adenocarcinoma|Pancreatic Cancer
Phase 2: Clear Cell Sarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CCS618 | P2 |
Completed |
Clear Cell Sarcoma |
2023-03-09 |
|
PANC003 (also known as âAVENGER 500â) | P3 |
Active, not recruiting |
Pancreatic Cancer|Adenocarcinoma |
2022-05-07 |